Marijuana has been used for medicinal and recreational purposes for thousands of years. Many people think of marijuana in the context of an illegal drug. Because of the antimarijuana attitude, research with cannabinoids was neglected for a long time. Although this substance is related to social problems, scientists are interested in its action and possible medicinal properties. Since the identification of the structure of Î 9--tetrahydrocannabinol, the main psychoactive ingredient of marijuana, there has been increased interest in this compound. Following the discovery of two cannabinoid receptors, CB1 and CB2 receptors, it was determined that CB1 receptors are in high density in the central nervous system while CB2 receptors are found primarily in the immune system. The endogenous cannabinoid ligands, anandamide and 2-arachidonoylglycerol, were observed in the central nervous system and peripheral tissues. Endocannabinoids differ from other "classical" neurotransmitters because they do not appear to be stored in synaptic vesicles, and they act as retrograde messengers within the brain. The endogenous cannabinoid signaling system includes cannabinoid receptors, their endogenous ligands called endocannabinoids, and the proteins for their synthesis and inactivation. The cannabinoid system appears to act as a neuromodulatory system. During the past ten years, the endogenous cannabinoid system has been implicated in a variety of physiological functions including pain reduction, motor regulation, learning, memory, and reward. Because obesity and eating disorders are prevalent, scientists are working at the molecular level to study the mechanisms controlling body weight and regulation of food intake. Several of the neuropeptides present in hypothalamic nuclei contribute to energy balance and food intake regulation. Endogenous cannabinoid and cannobinoid receptors are found in the hypothalamus and are associated with the regulation of food intake. Although the mechanisms whereby cannabinoids influence food intake remain unclear, results suggest that the cannabinoid system will be an important target in future studies in obesity. Most research on cannabinoids has focused on their role in food intake regulation in mammalian species. It is important to determine the role of endocannabinoids in other species. The effect of intracerebroventricular injection of agonists and antagonists of both CB1 and CB2 receptors in 8 to 11 week-old male Single Comb White Leghorn and 3 to 6 weeks old male broilers was investigated. It was found that agonists of both the CB1 and CB2 receptor increased food intake significantly; however, the CB2 receptor agonist had a stronger and longer lasting effect. Antagonists of both receptors decreased food intake significantly. The CB1 receptor antagonist appeared to block both cannabinoid receptors in birds, whereas the CB2 receptor antagonist did not block both receptors. Previous studies have indicated that the CB2 receptor is found only outside the brain and spinal cord, and is involved with the immune system. From the present results, it appears that both cannabinoid receptors are present in the chicken brain. Furthermore, the CB2 receptor may also be localize in the chicken brain. There are also differences in cannabinoid system between Leghorn and broilers. / Master of Science

L'étude de l'impact des facteurs environnementaux sur les effets à long-terme des psychostimulants a montré que des facteurs négatifs, comme le stress, augmentent le risque de développer une addiction, alors que des facteurs positifs, comme l'exposition à des conditions stimulantes, le réduisent. Une partie de cette thèse a consisté à rechercher les mécanismes neurobiologiques et cellulaires qui sous-tendent cette influence environnementale. Ainsi, l'exposition d'animaux à un environnement enrichi (EE), qui procure des conditions stimulantes, diminue leur niveau d'anxiété, un effet qui serait en partie lié à la régulation de gènes appartenant au système cannabinoïde endogène (SCE) dans des régions impliquées dans la réactivité au stress (article 1). Par ailleurs, nos travaux ont mis en évidence des limites de l'exposition à l'EE : quand celle-ci est interrompue, ses effets bénéfiques sont perdus et la vulnérabilité à la cocaïne est même augmentée. Ceci s'expliquerait par l'apparition d'un état émotionnel négatif, associé à une activation du facteur CREB dans l'amygdale étendue, une région carrefour entre la récompense et le stress (article 2). Nous nous sommes aussi intéressés à la toxicité de la méthamphétamine et à sa modulation par le SCE, pour lequel des propriétés neuroprotectives avaient déjà été suggérées. Ainsi, une stimulation pharmacologique du SCE permet de prévenir la neurotoxicité dopaminergique induite par la méthamphétamine (article 3). Nos résultats soulignent la complexité d'utilisation des manipulations environnementales et mettent en lumière les capacités protectives du SCE contre la dépendance et la neurotoxicité engendrées par les psychostimulants. / Studies of the impact of environmental factors on the long-term effects of psychostimulants have shown that negative factors, such as stress, increase the risk of developing drug addiction, while positive factors, such as exposure to stimulating conditions, reduce it. The first aim of this thesis work was to look for the neurobiological and cellular mechanisms that underlie this environmental influence. We found that exposure of animals to stimulating enriched environments (EE) reduces anxiety levels, an effect that may be partly related to the regulation of genes belonging to the endogenous cannabinoid system (ECS) in regions involved in stress reactivity (Article 1). In addition, our work has highlighted some limitations of the exposure to EE since discontinuation of enrichment results not only in the loss of its beneficial effects but also in increased vulnerability to cocaine. This effect is associated with emotional distress associated and changes in the activity of the transcription factor CREB in the extended amygdala, an interface region between reward and stress processes (Article 2). We also investigated whether ECS, for which neuroprotective properties have already been suggested, could reduce the brain toxicity induced by methamphetamine. We found that pharmacological stimulation of ECS provides protection against the methamphetamine-induced dopaminergic neurotoxicity (Article 3). Our results highlight the complex consequences of environmental conditions on brain and behavior and highlight the protective role of ECS against both addiction and neurotoxicity induced by psychostimulants.

La schizophrénie est une maladie complexe et a une prévalence approximative de 1% dans la population générale. Au sein des paradigmes neurochimiques, la théorie étiologique de la dopamine est celle qui prévaut alors que sont de plus en plus impliqués d’autres circuits de neurotransmission comme celui du glutamate. En clinique, les patients atteints de schizophrénie ont une grande propension à consommer des substances, particulièrement du cannabis. Nous avons cherché à étayer l’hypothèse d’un désordre du système cannabinoïde endogène, un important neuromodulateur. Ce mémoire propose d’abord dans un premier article une revue exhaustive de la littérature explorant le système endocannabinoïde et ses implications dans la schizophrénie. Puis, nous exposons dans un second article les résultats d’une recherche clinique sur les endocannabinoïdes plasmatiques dans trois groupes de sujets avec schizophrénie et/ou toxicomanie, pendant 12 semaines. Nous avons observé un effet miroir de deux ligands endocannabinoïdes, l’anandamide et l’oleylethanolamide, qui étaient élevés chez les patients avec double diagnostic et abaissés chez les toxicomanes, au début de l’étude. Au terme de l’étude, l’élévation des endocannabinoïdes s’est maintenue et nous avons supposé un marqueur de vulnérabilité psychotique dans un contexte de consommation. Finalement, nous avons analysé les résultats en les intégrant aux connaissances moléculaires et pharmacologiques ainsi qu’aux théories neurochimiques et inflammatoires déjà développées dans la schizophrénie. Nous avons aussi tenu compte des principales comorbidités observées en clinique: la toxicomanie et les troubles métaboliques. Cela nous a permis de proposer un modèle cannabinoïde de la schizophrénie et conséquemment des perspectives de recherche et de traitement. / Schizophrenia is a complex disease that has 1% worldwide prevalence. Dopamine etiological theory leads neurochemical paradigms although glutamate hypothesis is gaining in importance among several neurotransmission circuits involved. Schizophrenia patients are more prone to substance use disorders, particularly to cannabis dependence, than the general population. Therefore, we have aimed to explain the hypothesis of a deregulation in the endogenous cannabinoid system, a very important neurodulator.  First, this thesis proposes in the first article an exhaustive literature review on the endocannabinoid system and its implications in schizophrenia. Then, we present results from our clinical research on plasmatic endocannabinoids in three groups of subjects with schizophrenia and/or substance use disorders, during twelve weeks. We have observed a mirror effect involving two endocannabinoid ligands, anandamide and oleylethanolamide, which were elevated in patients with dual diagnosis and reduced in patients with only substance use disorders. At the end of the study, it seems that endocannabinoid elevation was maintained and we supposed a vulnerability to psychosis in a substance use disorder context.   Finally, we analyzed our results by integrating explanations from molecular biology and neuropharmacology and also from neurochemical and inflammatory theories already well-known in schizophrenia. We also considered the main comorbidities observed in clinic such as substance use and metabolic disorders. Then, we proposed an endogenous cannabinoid model of schizophrenia. Ultimately, this thesis suggested research perspectives and potential treatments.

The endogenous cannabinoids (endocannabinoids) anandamide (AEA) and 2-arachidonylglycerol (2-AG) exert their effects predominantly through cannabinoid CB1 and CB2 receptors, but these actions are short-lived because of rapid hydrolysis by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. Selective inhibition of either enzyme elevates CNS levels of the appropriate endocannabinoid and produces analgesic effects with fewer psychomimetic side effects than Δ9-tetrahydrocannabinol (THC), the primary active constituent of marijuana. While cannabinoid receptor agonists and FAAH inhibitors reliably produce anti-inflammatory and anti-hyperalgesic effects in the carrageenan test and other inflammatory pain models, much less is known about the consequences of inhibiting MAGL in these assays. Here, we tested whether the selective MAGL inhibitor JZL184 would reduce nociceptive behavior in the carrageenan test. JZL184 significantly attenuated carrageenan-induced paw edema and mechanical allodynia, whether administered before or after carrageenan. Complementary genetic and pharmacological approaches revealed that JZL184’s anti-allodynic effects required both CB1 and CB2 receptors, but only CB2 receptors mediated its anti-edematous actions. Importantly, the anti-edematous and anti-allodynic effects of JZL184 underwent tolerance following repeated injections of high dose JZL184 (16 or 40 mg/kg), but repeated administration of low dose JZL184 (4 mg/kg) retained efficacy. Interestingly, the anti-allodynic effects of the combination of low dose of JZL184 (4mg/kg) and high dose of the selective and long-acting FAAH inhibitor PF-3845 (10 mg/kg) was augmented compared with each drug alone. On the contrary, the combination treatment did not reduce edema more than either JZL184 or PR-3845 given alone. These results suggest that low doses of MAGL inhibitors alone or in combination with FAAH inhibitors, reduce inflammatory nociception through the activation of both CB1 and CB2 receptors with no evidence of tolerance following repeated administration.

La schizophrénie est une maladie complexe et a une prévalence approximative de 1% dans la population générale. Au sein des paradigmes neurochimiques, la théorie étiologique de la dopamine est celle qui prévaut alors que sont de plus en plus impliqués d’autres circuits de neurotransmission comme celui du glutamate. En clinique, les patients atteints de schizophrénie ont une grande propension à consommer des substances, particulièrement du cannabis. Nous avons cherché à étayer l’hypothèse d’un désordre du système cannabinoïde endogène, un important neuromodulateur. Ce mémoire propose d’abord dans un premier article une revue exhaustive de la littérature explorant le système endocannabinoïde et ses implications dans la schizophrénie. Puis, nous exposons dans un second article les résultats d’une recherche clinique sur les endocannabinoïdes plasmatiques dans trois groupes de sujets avec schizophrénie et/ou toxicomanie, pendant 12 semaines. Nous avons observé un effet miroir de deux ligands endocannabinoïdes, l’anandamide et l’oleylethanolamide, qui étaient élevés chez les patients avec double diagnostic et abaissés chez les toxicomanes, au début de l’étude. Au terme de l’étude, l’élévation des endocannabinoïdes s’est maintenue et nous avons supposé un marqueur de vulnérabilité psychotique dans un contexte de consommation. Finalement, nous avons analysé les résultats en les intégrant aux connaissances moléculaires et pharmacologiques ainsi qu’aux théories neurochimiques et inflammatoires déjà développées dans la schizophrénie. Nous avons aussi tenu compte des principales comorbidités observées en clinique: la toxicomanie et les troubles métaboliques. Cela nous a permis de proposer un modèle cannabinoïde de la schizophrénie et conséquemment des perspectives de recherche et de traitement. / Schizophrenia is a complex disease that has 1% worldwide prevalence. Dopamine etiological theory leads neurochemical paradigms although glutamate hypothesis is gaining in importance among several neurotransmission circuits involved. Schizophrenia patients are more prone to substance use disorders, particularly to cannabis dependence, than the general population. Therefore, we have aimed to explain the hypothesis of a deregulation in the endogenous cannabinoid system, a very important neurodulator.  First, this thesis proposes in the first article an exhaustive literature review on the endocannabinoid system and its implications in schizophrenia. Then, we present results from our clinical research on plasmatic endocannabinoids in three groups of subjects with schizophrenia and/or substance use disorders, during twelve weeks. We have observed a mirror effect involving two endocannabinoid ligands, anandamide and oleylethanolamide, which were elevated in patients with dual diagnosis and reduced in patients with only substance use disorders. At the end of the study, it seems that endocannabinoid elevation was maintained and we supposed a vulnerability to psychosis in a substance use disorder context.   Finally, we analyzed our results by integrating explanations from molecular biology and neuropharmacology and also from neurochemical and inflammatory theories already well-known in schizophrenia. We also considered the main comorbidities observed in clinic such as substance use and metabolic disorders. Then, we proposed an endogenous cannabinoid model of schizophrenia. Ultimately, this thesis suggested research perspectives and potential treatments.